BIOCLI CONSULT
ActiveBIOCLI CONSULT has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3k and a net result of €155k. Equity is shrinking by ~49.6% per year across the filed fiscal years. Its solvency ranks better than 15% of 524 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.9% (low).
Checked score
Score 2025
61
/ 100
Healthy
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency26=
Growth58=
Track record94
Bankruptcy probability, 12 months
0.9%
Low
0%0.5%1.5%4%10%≥ 25%
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
1%
Return on assets
51.1%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 15% of 524 sector peers (2025).
NBB · sector comparisonPosition among 524 sector peers
Solvency
better than 15%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
31 d early
2024
31 d early
2023
29 d late
2022
30 d late
2021
31 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
23-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€3k▼ 46.7%
2024 · €6k
2021: €45k
2022: €145k
2023: €256k
2024: €6k
2021 → 2025
Total assets
€303k▼ 24.1%
2024 · €399k
2021: €71k
2022: €193k
2023: €294k
2024: €399k
2021 → 2025
Net result
€155k▲ 19.7%
2024 · €129k
2021: €42k
2022: €100k
2023: €111k
2024: €129k
2021 → 2025
Working capital
€-53
2024 · €3k
2021: €45k
2022: €145k
2023: €253k
2024: €3k
2021 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€45k-€145k▲ 221%€256k▲ 76.3%€6k▼ 97.8%€3k▼ 46.7%
Operating result€58k-€125k▲ 118%€144k▲ 15.1%€168k▲ 16.4%€202k▲ 20.1%
Net result€42k-€100k▲ 137%€111k▲ 10.8%€129k▲ 16.5%€155k▲ 19.7%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has risen four years in a row; 2025 is 20% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €303k
Fixed assets
€3k▲ 34.9%
Current assets
€300k▼ 24.4%
Equity and liabilities €303k
Equity
€3k▼ 46.7%
Debt
€300k▼ 23.8%
The debt ratio rises from 98.6% to 99.0%. Equity and debt are lower.
Key figures and ratios
EBITDA
€203k▲
2024 · €169k
Cash flow
€156k▲
2024 · €131k
Solvency
1.0%▼
2024 · 1.4%
Current ratio
1.00▼
2024 · 1.01
Quick ratio
1.00▼
2024 · 1.01
Debt / equity
99.27▲
2024 · 69.47
ROA
51.1%▲
2024 · 32.4%
Interest coverage
57.50▼
2024 · 109.87
Debt
€300k▼
2024 · €393k
Debt ≤ 1 year
€300k▼
2024 · €393k
Income taxes
€46k▲
2024 · €38k
A ratio outside any meaningful range has been withheld (balance sheet total €303k, equity €3k).
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€399k€303k▼
Fixed assets21/28€2k€3k▲
Tangible fixed assets22/27€2k€3k▲
Furniture and vehicles24€2k€3k▲
Current assets29/58€397k€300k▼
Amounts receivable within one year40/41€6k€622▼
Trade receivables40€6k-
Other amounts receivable41-€622
Cash at bank and in hand54/58€293k€198k▼
Deferred charges and accrued income490/1€98k€102k▲
Equity and liabilities
Total equity and liabilities10/49€399k€303k▼
Equity10/15€6k€3k▼
Contributions10/11€3k€3k=
Profit (loss) carried forward14€3k€19▼
Amounts payable17/49€393k€300k▼
Amounts payable within one year42/48€393k€300k▼
Trade debts44€2k€2k▼
Suppliers440/4€2k€2k▼
Taxes, remuneration and social security45€11k€11k▲
Taxes450/3€10k€9k▼
Remuneration and social security454/9€1k€3k▲
Other amounts payable47/48€380k€287k▼
Income statement
Code20242025
Goods, raw materials, services and sundry goods60/61€133k-
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1k€2k▲
Other operating charges640/8€1k€2k▲
Gross operating margin9900€171k€205k▲
Operating profit (loss)9901€168k€202k▲
Financial income75/76B€1k€3k▲
Recurring financial income75€1k€3k▲
Financial charges65/66B€2k€4k▲
Recurring financial charges65€2k€4k▲
Profit (loss) for the period before taxes9903€168k€201k▲
Income taxes67/77€38k€46k▲
Profit (loss) for the period9904€129k€155k▲
Profit (loss) for the period to be appropriated9905€129k€155k▲
Appropriation of the result
Profit (loss) to be appropriated9906€383k€157k▼
Profit (loss) brought forward from the previous period14P€253k€3k▼
Profit to be distributed694/7€380k€157k▼
Return on contributions (dividend)694€380k€157k▼
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
30-06
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2021net €155k ▲19.7%
Operating result €202k, net result €155k, both a record.
30-06
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
29-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 29 days late
2023
31-12
Financial
Equity above €200kEq €256k ▲76.3%
3 profitable years in a row build equity to €256k.
30-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 30 days late
2022
31-12
Financial
Equity above €100kEq €145k ▲221%
2 profitable years in a row build equity to €145k.
30-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Jurbise · 1 establishment unit since 2021
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Chemin du Prince(EL) 1617050 JurbiseGround area
1,994 m²
Building footprint
243 m²
Parcel 53023B0192/00M008, Wallonia. Linked by address, not a title deed.
1 establishment unit
BIOCLI CONSULT
since 20212.320.051.344
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 53023B0192/00M008 | Wallonia | 1,994 m² | 1 · 243 m² | - |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Minerva Pharma Consulting
BE 0798.842.609
Keerbergen · Eq €3k
Snowcap
BE 0782.424.863
Gent · Eq €4k
Obvio Laboratories
BE 0763.445.923
Ukkel · Eq €3k
WE ARE REBEL
BE 1022.159.373
Evere · Eq €4k
Logibot
BE 1030.383.092
Huldenberg · Eq €4k
Of 1,177 companies in sector 72109 we hold annual accounts for 715. 96 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded11-07-2021
Fiscal year end31-12
Activities, NACEBEL
72109Other research and development on natural sciences
86901Human health activities
86910Medical imaging and medical laboratories
Sources
Crossroads Bank for EnterprisesNational Bank · 5 filingsAddress and cadastre registers
Data from official sources, last processed on 23-09-2026. Scores and ratios are computed by Checked and are not a credit decision.